AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Alexandria today, you need to believe in the long term value of its life science campuses despite recent revenue pressure, rising vacancies, and capital markets uncertainty. The new US$1.00 billion subordinated, fixed‑to‑floating note adds long duration funding and interest rate sensitivity, but it does not fundamentally change the near term demand risk from cautious biotech tenants or the pressure on same property NOI.
The most relevant recent announcement here is the company’s Q2 2026 results, which showed lower quarterly revenue but improved year to date profitability after prior impairments. Against that backdrop, issuing a junior, unsecured, variable rate note extends Alexandria’s debt stack while its buyback remains unused, which matters for how management balances liquidity, development funding, and the key catalyst of stabilizing occupancy and earnings.
Yet investors should also be aware that concentrated life science clusters, large capital needs, and rising cap rates could all interact with this new subordinated debt in ways that...
Read the full narrative on Alexandria Real Estate Equities (it's free!)
Alexandria Real Estate Equities' narrative projects $2.7 billion revenue and $479.3 million earnings by 2029.
Uncover how Alexandria Real Estate Equities' forecasts yield a $51.00 fair value, a 5% downside to its current price.
Compared with the baseline, the most optimistic analysts were already baking in revenue near US$2.8 billion and earnings of about US$485 million by 2029, so if you think mega campus leasing really will outpace rising capital costs and competitive supply, this bond deal might reinforce that upbeat view or cause you to reassess it once the full financing picture becomes clearer.
Explore 6 other fair value estimates on Alexandria Real Estate Equities - why the stock might be worth 14% less than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com